Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis

Linhui Zhu, Xuan Ye, Youjun She, Wensheng Liu, Kiyoshi Hasegawa, Roberta Elisa Rossi, Qiong Du, Qing Zhai